A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants

Healthy Clinical Trial

Official title:

Disposition of [14C]-LY3437943 Following Subcutaneous Administration in Healthy Male Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05757531
• Other study ID #: 18217
• Secondary ID: J1I-MC-GZBG
• Status: Completed
• Phase: Phase 1
• Start date: March 17, 2023
• Est. completion date: June 23, 2023

Study information

• Verified date: July 2023
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to is to look at how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it in healthy male participants. This study will involve a single dose of 14C radiolabeled LY3437943. his means that a radioactive tracer substance, C14, will be incorporated into the study drug to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine, feces and expired air.

The study will last up to approximately 15 weeks including the screening period of 28 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: June 23, 2023
• Est. primary completion date: June 23, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Male participants who are overtly healthy as determined by medical evaluation

• Have a body mass index within the range 18.5 to 32.0 kilograms per meter squared (kg/m²)

• Have clinical laboratory test results within normal reference range for the population or investigative site, or results outside the normal reference range that are judged to be not clinically significant by the investigator. Participants with dyslipidemia may be included in the study, at the discretion of the investigator, as long as they fulfill other eligibility criteria

• Have venous access sufficient to allow for blood sampling as per the protocol

• Are willing to receive study treatment by SC injections

• Have a history of a minimum of 1 bowel movement per day

• Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria:

• Have a clinically significant abnormal blood pressure and/or pulse rate as determined by the investigator at screening or check-in

• Have significant history of or current cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the IP; or of interfering with the interpretation of data

• Have evidence of significant active neuropsychiatric disease, as determined by the investigator

• Show evidence of HIV infection and/or positive HIV antibodies, hepatitis C and/or positive hepatitis C antibody, hepatitis B and/or positive hepatitis B surface antigen

• Have a history of constipation or have had acute constipation within 3 weeks prior to check-in

• Have evidence of active renal disease (eg, diabetic renal disease, polycystic kidney disease) or an estimated creatinine clearance of less than 70 mL/minute, calculated using the Chronic Kidney Disease-Epidemiology equation

• Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) and/or elevation in serum amylase or lipase (greater than 1.5-fold the ULN) at screening

• Have used or plan to use over-the-counter or prescription medication, and/or dietary or herbal supplements (with the exception of vitamin supplements, acetaminophen and/or thyroid replacement therapy) within 14 days or 5 half-lives (whichever is longer) prior to dosing and for the duration of the study, including any medications that reduce GI motility, including, but not limited to, anticholinergics, antispasmodics, 5 hydroxytryptamine-3 receptor antagonists, dopamine antagonists, and opiates

• Have had exposure to significant radiation within 12 months prior to dosing (eg, serial x-ray or CT scans, barium meal, being employed in a job requiring radiation exposure monitoring)

• Have participated in any clinical trial involving a radiolabeled substance within the past 12 months

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• [¹4C]-LY3437943
Administered SC.

Locations

Country	Name	City	State
United States	Covance Clinical Research Unit	Madison	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered	Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered	Predose up to 63 days post dose
Primary	Fecal Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered	Fecal Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered	Predose up to 63 days post dose
Secondary	PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC (0-8)) of Total Radioactivity and [¹4C]-LY3437943	PK: AUC (0-8) of Total Radioactivity and [¹4C]-LY3437943	Predose up to 63 days post dose
Secondary	PK: Maximum Concentration (Cmax) of Total Radioactivity and [¹4C]-LY3437943	PK: Cmax of Total Radioactivity and [¹4C]-LY3437943	Predose up to 63 days post dose
Secondary	Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable)	Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable)	Predose up to 63 days post dose
Secondary	Total Number of Metabolites of LY3437943	Total Number of Metabolites of LY3437943	Predose up to 63 days post dose